In English | En español
Questions About Cancer? 1-800-4-CANCER

Study of Tamoxifen and Raloxifene (STAR) Trial

  • Updated: 02/02/2011

Page Options

  • Print This Page
  • Email This Document

The information and links on this page are no longer being updated and are provided for reference purposes only.

Related Pages

  • Breast Cancer Home Page
    NCI's gateway for information about breast cancer.
  • U.S. Task Force: Chemoprevention of Breast Cancer
    The U.S. Preventive Services Task Force has issued two recommendations concerning the use of prescription medicines such as tamoxifen in the prevention of breast cancer.
  • Estrogen Receptors, Tamoxifen, and Raloxifene
    Describes the hormone estrogen and its receptor. Explains the relationship of estrogen and its receptor to breast cancer and the risks and benefits of reducing cancer risk with drugs called antiestrogens and selective estrogen receptor molecules (SERMs).

STAR Background

The following links will take you to press releases and other materials concerning the STAR trial that have been prepared by the National Cancer Institute's Office of Communications and Education.

En Español

En Français

  • Les premiers résultats de l'étude STAR (Study of Tamoxifen and Raloxifene)
    Les premiers résultats de l'étude STAR (Study of Tamoxifen and Raloxifene) montrent que le raloxifène, habituellement utilisé dans la prévention et le traitement de l'ostéoporose chez la femme ménopausée, est aussi efficace que le tamoxifène à réduire le risque de cancer du sein chez la femme ménopausée déjà à risque.

In English